IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Acquired by Mediolanum International Funds Ltd

Mediolanum International Funds Ltd lifted its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 44.7% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 39,470 shares of the company’s stock after buying an additional 12,201 shares during the period. Mediolanum International Funds Ltd’s holdings in IDEXX Laboratories were worth $16,251,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. International Assets Investment Management LLC lifted its position in IDEXX Laboratories by 52,746.0% during the 3rd quarter. International Assets Investment Management LLC now owns 528,460 shares of the company’s stock worth $2,669,890,000 after acquiring an additional 527,460 shares during the period. Assenagon Asset Management S.A. lifted its holdings in shares of IDEXX Laboratories by 265.6% during the fourth quarter. Assenagon Asset Management S.A. now owns 435,049 shares of the company’s stock worth $179,867,000 after purchasing an additional 316,048 shares during the period. Seilern Investment Management Ltd purchased a new stake in IDEXX Laboratories in the fourth quarter valued at approximately $113,104,000. Vontobel Holding Ltd. increased its holdings in IDEXX Laboratories by 3,325.0% in the 3rd quarter. Vontobel Holding Ltd. now owns 220,159 shares of the company’s stock worth $111,229,000 after buying an additional 213,731 shares during the period. Finally, Healthcare of Ontario Pension Plan Trust Fund purchased a new position in IDEXX Laboratories during the 2nd quarter worth approximately $47,542,000. 87.84% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other IDEXX Laboratories news, Director Sophie V. Vandebroek sold 344 shares of the business’s stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total transaction of $144,631.36. Following the completion of the sale, the director now directly owns 905 shares in the company, valued at approximately $380,498.20. The trade was a 27.54 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 2.11% of the stock is currently owned by company insiders.

IDEXX Laboratories Stock Performance

Shares of IDXX stock opened at $423.99 on Friday. The company has a current ratio of 1.42, a quick ratio of 1.03 and a debt-to-equity ratio of 0.32. IDEXX Laboratories, Inc. has a 12-month low of $398.50 and a 12-month high of $583.39. The business’s 50 day moving average is $423.93 and its two-hundred day moving average is $454.80. The company has a market capitalization of $34.72 billion, a P/E ratio of 40.89, a P/E/G ratio of 3.60 and a beta of 1.36.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Thursday, October 31st. The company reported $2.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.69 by $0.11. The firm had revenue of $975.50 million for the quarter, compared to analyst estimates of $980.32 million. IDEXX Laboratories had a return on equity of 55.42% and a net margin of 22.53%. The business’s revenue was up 6.6% on a year-over-year basis. During the same quarter last year, the firm posted $2.53 EPS. Analysts expect that IDEXX Laboratories, Inc. will post 10.44 EPS for the current fiscal year.

Wall Street Analyst Weigh In

IDXX has been the topic of a number of research reports. Stifel Nicolaus cut their price objective on shares of IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating on the stock in a research note on Thursday, October 10th. Morgan Stanley cut their price target on IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating on the stock in a research report on Wednesday. StockNews.com raised IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Thursday, November 28th. Barclays dropped their target price on IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating on the stock in a report on Monday, November 4th. Finally, Leerink Partnrs raised IDEXX Laboratories to a “strong-buy” rating in a report on Monday, December 2nd. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $517.29.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.